GHRH ANALOG + GHRELIN RECEPTOR AGONISM
CJC-1295 (without DAC) + Ipamorelin
A formulation label commonly applied to shorter-acting GHRH analogs combined with ipamorelin; the label should not be treated as equivalent to CJC-1295 with DAC.
At a Glance
PRIMARY RESEARCH AREAS
GHRH signaling; ghrelin-receptor signaling; growth hormone secretion; endocrine pharmacology
EVIDENCE LEVEL
Direct controlled evidence for the combined formulation is limited; component-level evidence should not be assumed to establish blend-level outcomes.
This profile provides an evidence-first overview of CJC-1295 (without DAC) + Ipamorelin. Direct controlled evidence for the combined formulation is limited; component-level evidence should not be assumed to establish blend-level outcomes.
Overview
A formulation label commonly applied to shorter-acting GHRH analogs combined with ipamorelin; the label should not be treated as equivalent to CJC-1295 with DAC. Interpretation remains limited to evidence attributable to the exact compound or formulation.
Research Context
CJC-1295 (without DAC) + Ipamorelin is commonly used as a label for a combination of two distinct growth-hormone signaling approaches: a shorter-acting growth hormone–releasing hormone (GHRH) analog and ipamorelin, a selective ghrelin-receptor agonist. Both pathways can stimulate growth hormone release from pituitary somatotrophs, but they act through different receptors and signaling mechanisms.
An important distinction is that “CJC-1295 without DAC” is not pharmacologically equivalent to the long-acting, DAC-conjugated CJC-1295 studied in several published human trials. The DAC modification substantially extends exposure. Research involving CJC-1295 with DAC therefore should not automatically be used to predict the pharmacokinetics, dosing behavior, efficacy, or safety of products labeled “CJC-1295 without DAC.”
Ipamorelin has been studied independently as a growth hormone secretagogue and is notable for its relative selectivity for GH release compared with some earlier growth hormone–releasing peptides. However, direct controlled human research evaluating the specific CJC-1295-without-DAC + ipamorelin combination is limited. Claims about effects on body composition, recovery, sleep, muscle growth, or fat loss should therefore be distinguished from what has actually been demonstrated for the combined formulation.
Mechanism / Biological Context
Overlapping research areas provide a rationale for studying the constituents together, but they do not establish additive or synergistic effects.
Published Research
Evidence for GLOW should be read as separate GHK-Cu, BPC-157, and thymosin beta-4 / TB-500 contexts rather than as evidence for a single tested product. The concise evidence matrix below summarizes the cellular, preclinical, and human landscape.
Limitations / What Remains Unknown
The largest limitation is the lack of controlled human trials evaluating CJC-1295 without DAC and ipamorelin together as a defined combination. Although both GHRH-receptor agonism and ghrelin-receptor agonism can stimulate growth hormone secretion, biological activity does not by itself establish clinically meaningful effects on body composition, recovery, sleep, physical performance, or healthy aging.
Another important limitation involves terminology. Much of the published human literature commonly associated with “CJC-1295” investigated the long-acting DAC-conjugated molecule. Removing the DAC modification changes the compound's pharmacokinetic behavior, so duration of exposure, GH and IGF-1 responses, and safety findings from DAC studies should not automatically be applied to products described as CJC-1295 without DAC.
Long-term safety of the specific combination also remains insufficiently characterized. Sustained or repeated manipulation of the GH/IGF-1 axis may have metabolic and physiological consequences that cannot be adequately predicted from short-duration secretagogue studies. Questions involving glucose regulation, fluid balance, cardiovascular effects, tissue growth, and other longer-term outcomes require appropriately designed clinical research.
Product identity presents an additional research challenge. “CJC-1295 without DAC” is sometimes used commercially for shorter-acting GHRH analog formulations, but nomenclature is not always consistent across research and commercial contexts. Analytical verification of molecular identity, purity, and formulation is therefore important when interpreting results.
Overall, the available evidence supports the underlying mechanisms of GHRH- and ghrelin-receptor-mediated GH release, but substantial uncertainty remains regarding the efficacy, optimal exposure, long-term safety, and clinical outcomes of the combined CJC-1295-without-DAC + ipamorelin formulation.
References
Profile-specific references are limited to records verified for the exact compound or formulation. Related-molecule evidence is explicitly distinguished from direct evidence.
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism.
Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism.
Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology.
Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research.
Evidence Landscape
Evidence involving individual constituents should be interpreted according to the exact compound, formulation, route, population and endpoint studied. Controlled human evidence specifically evaluating the combined 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 formulation has not been established.
CELLULAR / IN-VITRO EVIDENCE
Cellular and receptor-level research provides the mechanistic basis for understanding how the two components are expected to act, but this level of evidence does not establish clinical outcomes.
GHRH analogs act at the growth hormone–releasing hormone receptor on pituitary somatotroph cells. Activation of this receptor engages intracellular signaling pathways that increase growth hormone synthesis and secretion. Experimental work with GHRH analogs has helped define the receptor-level mechanisms involved in pituitary GH release and supports the biological plausibility of shorter-acting GHRH analogs producing transient stimulation of this pathway.
Ipamorelin acts primarily through the growth hormone secretagogue receptor, GHS-R1a, the principal signaling receptor for ghrelin. Receptor and pharmacology studies have shown that ipamorelin behaves as a GH secretagogue through this pathway and differs mechanistically from direct GHRH-receptor activation.
Because these receptors are distinct but converge on growth hormone secretion from pituitary somatotrophs, combined signaling has a plausible mechanistic basis for additive or synergistic GH release. However, receptor activation observed in cellular systems cannot determine whether a specific combination will produce meaningful changes in body composition, recovery, performance, or other clinical outcomes in humans.
In vitro findings are therefore best interpreted as evidence of mechanism rather than evidence of therapeutic effect.
ANIMAL / PRECLINICAL EVIDENCE
Preclinical studies support the ability of growth hormone secretagogues and GHRH-pathway agonists to stimulate GH release, but the available animal evidence does not directly establish the effects of the specific CJC-1295-without-DAC + ipamorelin combination in humans.
Experimental studies of ipamorelin characterized it as a potent and relatively selective growth hormone secretagogue. In animal models, ipamorelin stimulated GH release with less accompanying stimulation of ACTH and cortisol than some earlier growth hormone–releasing peptides, helping establish its pharmacologic profile.
Preclinical research involving GHRH analogs has likewise demonstrated that activation of the GHRH receptor can increase pituitary GH secretion and influence downstream IGF-1 signaling. These studies contributed to development of longer-acting GHRH analogs, including DAC-modified CJC-1295.
Some animal studies of GH-secretagogue signaling have also examined effects on appetite, gastrointestinal function, metabolism, tissue repair, and other physiological processes. However, results vary substantially by compound, species, dose, and experimental model and should not be assumed to predict outcomes from CJC-1295 without DAC plus ipamorelin.
Overall, preclinical evidence supports the biological plausibility of stimulating the GH axis through these pathways, but controlled human studies are required to determine whether those mechanisms translate into meaningful benefits or risks.
Human Evidence
Human evidence is available for both CJC-1295 and ipamorelin individually, but direct clinical evidence for the specific CJC-1295-without-DAC + ipamorelin combination remains limited.
In healthy adults, long-acting CJC-1295 containing the Drug Affinity Complex (DAC) produced sustained increases in circulating growth hormone and IGF-1 after administration. These studies demonstrated that CJC-1295 can meaningfully alter GH-axis signaling in humans, but the DAC formulation has substantially different pharmacokinetics from the shorter-acting non-DAC form.
Ipamorelin has also been evaluated in healthy male volunteers. Human pharmacokinetic and pharmacodynamic studies showed that it can trigger a measurable, dose-related growth hormone response, supporting its activity as a growth hormone secretagogue.
The key evidence gap is that these findings come from studies of the individual compounds or related formulations. There is currently little high-quality controlled human research showing that the combined use of CJC-1295 without DAC and ipamorelin produces specific improvements in muscle mass, fat loss, recovery, sleep quality, athletic performance, or longevity.
For that reason, human evidence supports the biological activity of the GH-secretagogue pathways, but not broad claims of established clinical benefit for the combination itself.
Key Findings by Research Area
• CJC-1295 without DAC and ipamorelin act through different upstream receptors that converge on pituitary growth hormone secretion.
• Human studies show that ipamorelin can produce a measurable, dose-related GH response.
• Human CJC-1295 studies have demonstrated increases in GH and IGF-1, but the best-characterized trials used the long-acting DAC formulation, not CJC-1295 without DAC.
• The biological rationale for combining GHRH-receptor and ghrelin-receptor signaling is plausible, but direct controlled human evidence for the specific combination remains limited.
• Claims involving muscle gain, fat loss, recovery, sleep, athletic performance, or longevity go beyond what has been established in controlled clinical research.
• More research is needed to determine the combination's long-term safety, pharmacokinetics, and clinically meaningful outcomes.
Safety & Tolerability Evidence
Safety conclusions require controlled, compound-specific human evidence. Mechanistic or related-compound evidence is not sufficient to establish safety.
Research Gaps & Interpretation
Priority gaps include clear compound characterization, independent replication, clinically meaningful endpoints, and longer-term follow-up.
Editorial Review
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, and distinction between preclinical, mechanistic, and human evidence.